Jazz Pharmaceuticals (JAZZ) PT Lowered at RBC as 'Lighter Pipeline Puts Commercial Execution in Spotlight'
Tweet Send to a Friend
RBC Capital analyst Gregory Renza lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $178.00 (from $179.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
